Scanmed S.A.

At Scanmed S.A. in Lublin, the clinical research focus is centered on gastroenterology and immune-mediated inflammatory diseases. The studies are exploring ways to improve treatment for Crohn’s disease, ulcerative colitis, and short bowel syndrome, with an emphasis on both symptom control and longer-term patient outcomes.

• Research in moderately to severely active ulcerative colitis is assessing a new therapy to better control inflammation and improve disease management.
• Studies in Crohn’s disease are evaluating treatment effectiveness and safety, including approaches aimed at both clinical and endoscopic improvement.
• Work in short bowel syndrome is focused on the long-term safety and tolerability of a treatment designed to support patients with intestinal failure.

Overall, the site is contributing to research that tests new treatment options, monitors safety, and seeks better control of chronic digestive and inflammatory conditions.

A major part of the trial portfolio at this hospital-based research site involves Crohn’s disease, especially cases that are moderately to severely active. These studies are designed to understand whether new or combined therapies can reduce disease activity and improve digestive health.

• Trials are examining the effectiveness and safety of guselkumab for people with Crohn’s disease.
• Another study is looking at a combination approach with ustekinumab to find early signs of benefit in patients with active disease.
• Researchers are also measuring changes in endoscopic disease severity to better understand treatment impact.

This line of research aims to improve both clinical outcomes and the way disease activity is assessed in everyday care.

The site is also involved in research on moderately to severely active ulcerative colitis, a chronic inflammatory disease of the large intestine. These studies are focused on testing whether newer therapies can provide better control of inflammation and support more durable symptom relief.

• One trial is evaluating the efficacy and safety of a treatment for ulcerative colitis.
• The research is aimed at helping patients whose disease remains difficult to manage with standard care.
• Outcomes are centered on treatment response and overall tolerability.

This work reflects a strong interest in advancing care for chronic immune-related gastrointestinal disease.

Another important area of investigation at Gastromed ZOZ is short bowel syndrome, a condition that can cause serious problems with nutrient and fluid absorption. The trial activity here is focused on evaluating whether a new treatment can support patients over the long term.

• Research is assessing the long-term safety and tolerability of a therapy for short bowel syndrome with intestinal failure.
• The goal is to better understand how treatment may help patients living with ongoing digestive challenges.
• This study adds to the site’s broader focus on complex digestive system disorders.

By studying both effectiveness and safety, the site is helping build evidence for more supportive care in this rare but serious condition.